As I indicated last week, I wanted to write about a specific dialog that occurred at the December 4, 2012 California Board of Pharmacy Enforcement Committee meeting. The important exchange came at the end of the meeting during the catchall agenda item called “General Discussions” when topics that are not on the agenda can be raised by Board members or the general public in attendance.
I received very sad news last night of the loss of another friend and co-worker in the serialization and track and trace industry. Bob Bergantino, most recently of Excellis Health Solutions, worked for SupplyScape at the same time I did. We didn’t work on any projects or sales together but Bob was such a cheerful and inviting person that I couldn’t help but know and love him. Bob had a magnetic personality and was full of wit, charm and love for everyone around him. We will all miss him. Continue reading Robert J. “Bob” Bergantino (1960-2012)→
Last week I attended the Enforcement Committee meeting of the California Board of Pharmacy. The value of attending these meetings is hard to extract. It helps to have a solid knowledge of the language of the pedigree law, understanding of the standards and technology being considered to meet it, and the history of how we got where we are today. Even with all that on your side it takes a lot of concentration during the meeting and after it is over to put it all into perspective and find the value.
While writing last Monday’s RxTrace essay I ran out of time before I could get to the point I originally intended to make, so here is the conclusion to my thoughts on the topic.
The point I wanted to make is that there is a big difference between the goal of serialization and that of most other anti-counterfeiting technologies. Most anti-counterfeiting technologies covered in Mark Davison’s essential book on the topic, “Pharmaceutical Anti-Counterfeiting, Combating the Real Danger from Fake Drugs“, are technologies that a given manufacturer chooses to place in or on their drug, or on their drug’s packaging so that they can later differentiate it from potential counterfeit versions. That is, so that they can later “authenticate” only the drugs that they truly manufactured.
Ed Silverman has just raised my awareness in his Pharmalot blog for today that the Wall Street Journal is reporting that the first physician has pleaded guilty to purchasing illegal foreign drugs in the counterfeit Avastin series of crimes from earlier this year. That’s swift justice and I love it. Apparently there are more to come. Hopefully it will serve to remind all physicians that they need to only buy from licensed and legitimate sources. Their patient’s lives depend their knowledge and skills… but also on their pharmaceutical buying practices
Rather than repeat Ed and WSJ, just go read the articles yourself by clicking here:
Counterfeiting of drugs has become a favorite activity of organized criminals and it negatively impacts the citizens of every country in the world. The pharma industry is multi-national, the criminals are multi-national, the patients that are harmed are multi-national. What we need now more than ever before is a multi-national approach to fighting these crimes.
…a comprehensive exploration of the intersection between healthcare supply chains, track and trace technology, standards and global regulatory compliance
DISCLAIMER: RxTrace contains some of the personal thoughts, ideas and opinions of RxTrace. The material contained in RxTrace is not legal advice. The writers of RxTrace are not lawyers. The reader must make their own decisions about the accuracy of the opinions expressed in RxTrace. Readers are encouraged to consult their own legal counsel and trading partners before taking any actions based on information found in RxTrace. RxTrace is not a vehicle for communicating the positions of any company, organization or individual other than RxTrace.